What is inclusion body myositis?

Inclusion Body Myositis (IBM) is a rare, progressive muscle disease characterized by chronic muscle inflammation and weakness. It is the most common acquired muscle disease in adults over 50, affecting approximately 20,000 people in the United States.

Sporadic IBM (sIBM), the most common form, is NOT inherited — it occurs randomly. However, about 67% of patients carry a specific HLA gene combination that makes them genetically susceptible. Hereditary Inclusion Body Myopathies (hIBM) are a separate group of genetic muscle diseases.

Is there a cure for IBM?

As of 2026, there are no FDA-approved treatments specifically for IBM. The disease is notoriously resistant to corticosteroids and immunosuppressive drugs. Physical therapy and adaptive strategies are the mainstay of management. Active research is underway with promising clinical trials.

Does IBM qualify for disability benefits?

Yes. IBM is listed under Section 11.15 (Disorders of the Peripheral Nervous System) in the SSA Blue Book for Social Security Disability Insurance (SSDI). The IBM Functional Rating Scale can support your application.

What exercises are safe with IBM?

Walking, aquatic therapy, light resistance training, balance training, and hand/finger exercises are all recommended for IBM patients. Start slowly, build over 6-12 weeks, and consult with a physical therapist who understands myositis.

Why is IBM often misdiagnosed?

IBM is frequently misdiagnosed as polymyositis, normal aging, fibromyalgia, ALS, or sarcopenia. The average diagnostic delay is 5-10 years from symptom onset because IBM shares symptoms with more common conditions.

How Common Is IBM? Large Study Reveals New Incidence Rates and Demographic Differences

Understanding how many people get IBM — and who is most at risk — is crucial for planning healthcare services, funding research, and ensuring patients receive timely diagnosis. A new large-scale study from England provides the most detailed picture yet.

What the Researchers Did

Researchers from King's College London and Pfizer analyzed data from the Clinical Practice Research Datalink (CPRD) Aurum database, which contains anonymized electronic health records from over 1,300 primary care practices in England. They combined primary care data with hospital episode statistics to identify cases of idiopathic inflammatory myopathies (IIM) — the group of autoimmune muscle diseases that includes IBM — diagnosed between 2002 and 2021.

The study identified 4,105 incident IIM cases: 1,590 with dermatomyositis (DM), 432 with IBM, and 2,083 with other IIM subtypes. IBM was only assigned for patients aged 45 years and over, as symptom onset before this age is uncommon.

Key Findings: How Common Is IBM?

The study found that IBM has an incidence rate of 0.50 per 100,000 person-years. To put that in plain language: in a population of 100,000 people, about 0.5 new IBM cases would be expected each year — or roughly 1 new case per 200,000 people annually.

For comparison, dermatomyositis had a slightly higher incidence (0.79 per 100,000 person-years), while other IIM subtypes combined had the highest incidence (1.03 per 100,000 person-years).

The point prevalence at the end of the study period (March 2021) was 0.005% for IBM — meaning about 1 in 20,000 people in England were living with IBM at that time.

Sex Differences: IBM Is More Common in Men

One of the most striking findings was the sex difference. While dermatomyositis and other IIM subtypes were more common in women, IBM was significantly more common in men. Females had a 27% lower incidence of IBM compared with males (adjusted incidence rate ratio 0.73).

This is consistent with clinical experience — IBM is often described as a disease that predominantly affects men over 50. The study provides robust population-based evidence confirming this pattern.

Age Distribution: IBM Primarily Affects Older Adults

IBM was overwhelmingly a disease of older adults. The median age at diagnosis was 68.6 years, compared to 56.2 years for dermatomyositis and 60 years for other IIM. The highest incidence was in the 70-79 age group.

Only 3.9% of IBM cases occurred in people aged 45-49, and no cases were identified before age 45 — consistent with the study's inclusion criteria and the clinical understanding that IBM rarely presents before middle age.

Ethnic Differences: Less Clear for IBM

Unlike dermatomyositis and other IIM subtypes, which showed substantial ethnic variation, IBM incidence did not differ significantly across ethnic groups. This is an important finding — it suggests that the biological factors driving IBM may be less influenced by ethnicity than those driving other forms of myositis.

Socioeconomic Factors: IBM Less Common in Deprived Areas

Interestingly, IBM incidence was lower in more deprived areas. People living in the most deprived areas had a 43% lower incidence of IBM compared with those in the least deprived areas. The researchers suggest this may reflect diagnostic delays or barriers to healthcare access in deprived populations, rather than a true protective effect of deprivation.

Incidence Has Increased Over Time — But Is It Real?

The raw number of IIM cases increased substantially over the 19-year study period. However, after adjusting for population aging, the age-standardized incidence remained fairly constant. This suggests the apparent increase is largely due to an aging population rather than a true rise in disease occurrence.

What This Means for IBM Patients

This study provides the most robust population-based estimates of IBM incidence to date. The findings confirm that IBM is a rare disease affecting primarily men over 65, with an incidence of roughly 1 in 200,000 people per year.

For patients, these numbers matter because they demonstrate that IBM is not "just aging" — it is a distinct disease with a specific demographic profile. The sex and age patterns also have implications for clinical trial design and healthcare planning.

The researchers conclude that "resource planning should account for these marked differences" in IIM subtype incidence across demographic groups. For IBM patients, this means continued advocacy for specialist services, research funding, and access to clinical trials.

Source

• Gordon P, McLean M, Czachorowski M, et al. "Epidemiology of idiopathic inflammatory myopathies: a population-based cohort in England, 2002-2021." RMD Open. 2026 Jul 15;12(3):e006966. doi: 10.1136/rmdopen-2026-006966. PMID: 42457214.